Fady Malik's Stock Option Exercise and Sales Plan

Fady Malik, an officer at Cytokinetics Inc, has filed a Form 144 detailing a plan to exercise stock options and sell the resulting shares. The filing indicates that Malik will exercise options to acquire 11,000 common shares on October 21, 2025, and plans to sell these shares on the same date. The aggregate market value of the shares to be sold is approximately $652,850. Additionally, the filing discloses Malik's recent sales of common shares under a 10b5-1 plan, totaling 12,000 shares sold over the past three months, with gross proceeds amounting to $546,487. The sales were executed at various dates between July 22, 2025, and October 7, 2025. The filing emphasizes that the securities to be sold were and will be received upon the exercise of stock options over the next three months.